Clinical trial NCT05150496: Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
Official title: A Phase IIb Randomized Double-Blinded Positive Controlled Trial to Evaluate the Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults Who Have Completed Two Doses of CoronaVac® or the mRNA Vaccine (Comirnaty) in Turkey
Study type: INTERVENTIONAL
Overall status: SUSPENDED
Phase: PHASE2
Conditions: COVID-19
Lead sponsor: Sinovac Biotech Co., Ltd
Sponsor class: INDUSTRY
First posted: 2021-12-09
Enrollment: 640
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the immunogenicity of using the high (1200SU) or medium (600SU) dose of CoronaVac® as the booster dose.

Detailed description: This is a randomized, double-blinded, and positive-controlled phaseⅡb clinical trial of 640 participants aged 18 years and above, who have completed 2 doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty) as the primary vaccination. Participants will be enrolled and randomly assigned into two arms at a ratio of 1:1 to receive a booster dose of medium-dose (600SU) or high-dose (1200SU) COVID-19 Vaccine. For those who were vaccinated with CoronaVac®, the booster dose will be given 3-8 months after their second dose. For those who were vaccinated with Comirnaty, the booster dose will be given 6-8 months after their second dose. Each participant will be collected 5.0 ml blood sample before vaccination and 14 days,3 months and 6 months after booster immunization.Immunogenicity assessments will be determined by neutralizing antibodies in all participants.In addition,all participants will be monitored for immediate reactions (within 30 minutes) after the booster dose vaccination, adverse events of special interest (AESIs) and serious adverse events (SAEs) for 12 months after booster dose inoculation. In addition, all participants in will be monitored for local and systemic solicited adverse events (AEs) within 7 days and the unsolicited AEs within 28 days.

Eligibility criteria: Inclusion Criteria:

* Healthy adults aged 18 years and above, who have received 2 prior doses of inactivated COVID-19 vaccine (CoronaVac®) or mRNA COVID-19 vaccine (Comirnaty), with the second dose given 3-8 months (for CoronaVac® recipients) and 6-8 months (for Comirnaty recipients) prior to the day of booster vaccination in the present study;
* Antigen rapid testing negative at the day of enrollment on site or with a PCR negative result within 72 hours before enrollment;
* The participants are able to understand and sign the informed consent voluntarily;
* Female participants who have a negative pregnancy test on the day of vaccination, and not currently breastfeeding;
* The participants are planning to be living in Turkey for the following 1 year after attending this study;
* The participants must be willing to provide verifiable identification (in accordance with the local regulations), has means to be contacted and to contact the investigator during the study.

Exclusion Criteria:

* History of confirmed or currently with the infection of SARS-CoV-2 prior to randomization;
* Any prior administration of another investigational coronavirus vaccine or current/planned simultaneous participation in another interventional study to prevent or treat COVID-19;
* Known allergy to vaccines or vaccine ingredients, and serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema;
* Serious chronic disease, serious cardiovascular disease, hypertension and diabetes that cannot be controlled by drugs, hepatorenal disease, malignant tumor, etc;
* Acute central nervous system diseases such as encephalitis/myelitis, acute disseminating encephalomyelitis, and related disorders;
* Receipt of blood/plasma products or immunoglobulins in the past 3 months before vaccination in this study;
* Participation in other studies involving study intervention within 30 days prior to vaccination in this study;
* Receipt of attenuated live vaccines in the past 14 days prior to vaccination in this study;
* Receipt of inactivated or subunit vaccines in the past 7 days prior to vaccination in this study;
* Acute exacerbation or presentation of stable chronic diseases (including but not limited to asthma, migraine, gastrointestinal disorder, etc.);
* Acute febrile illness with axillary temperature \>37.5°C on the day of vaccination; enrollment could be considered if the fever is absent for 72 hours prior to vaccination;
* According to the investigator's judgment, the participant has any other factors that might interfere with the results of the clinical trial or pose additional risk to the participant due to participation in the study.

Primary outcomes:
measure: Immunogenicity index-GMT of neutralizing antibodies
timeFrame: 14 days (14-28 days) after the booster dose vaccination
Secondary outcomes:
measure: Immunogenicity index-Seropositivity rate of neutralizing antibodies
timeFrame: 14 days (14-28 days) after the booster dose vaccination
measure: Immunogenicity index-GMI of neutralizing antibodies
timeFrame: 14 days (14-28 days) after the booster dose vaccination
measure: Immunogenicity index-The seropositivity rate of neutralizing antibody
timeFrame: At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination
measure: Immunogenicity index-GMT of neutralizing antibody
timeFrame: At 3 (±2 weeks) and 6 (±2 weeks) months after the booster dose vaccination
measure: Safety index-Occurrence, intensity, duration, and relationship of solicited local and systemic AEs
timeFrame: 7 days following the booster dose vaccination
measure: Safety index-Occurrence, intensity, duration, and relationship of unsolicited AEs
timeFrame: 28 days post booster vaccination
measure: Safety index-Occurrence and relationship of SAEs
timeFrame: From the booster dose to 12 months post booster vaccination
measure: Safety index-Occurrence and relationship of AESI
timeFrame: From the booster dose to 12 months post booster vaccination
Other outcomes:
measure: Immunogenicity index-The seropositivity rate of neutralizing antibodies
timeFrame: Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
measure: Immunogenicity index-GMT of neutralizing antibodies
timeFrame: Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
measure: Immunogenicity index-GMI of neutralizing antibodies
timeFrame: Before vaccination, 14 days (14-28 days) , 3-month (±2 weeks), and 6-month (±2 weeks) after the booster dose vaccination
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University Faculty of Medicine, Department of Internal Diseases / Infectious Diseases and Clinical Microbiology Unit
city: Ankara
country: Turkey
facility: Republic of Turkey Ministry of Health Ankara City Hospital Department of Internal Diseases
Study officials:
affiliation: Republic of Turkey Ministry of Health Ankara City Hospital Department of Internal Diseases
name: Enes Seyda Şahiner, Doctor
role: PRINCIPAL_INVESTIGATOR
References: